{'fraction_non_alphanumeric': 0.044296788482835, 'fraction_numerical': 0.035437430786267994, 'mean_word_length': 5.277777777777778, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Influences of the PPARα-L162V polymorphism on plasma HDL2-cholesterol response of abdominally obese men treated with gemfibrozil

Purpose: The effect of gemfibrozil is mediated by the activation of peroxisome proliferator-activated receptor alpha (PPARα). The objective of this study was to determine whether the lipid response to gemfibrozil therapy is influenced by the PPARα-L162V polymorphism.Methods: Sixty-three abdominally obese men were randomly assigned to a 6-month-intervention program with either receiving a placebo (N = 31) or gemfibrozil (N = 32).Results: In response to gemfibrozil therapy, L162-homozygotes exhibited a 5.5% increase in high-density lipoprotein 2 cholesterol (HDL2-C) levels compared with a 50.0% increase among carriers of the V162 allele (P = 0.03).Conclusion: These results suggest that the HDL2-C response to gemfibrozil is modulated by the PPARα-L162V polymorphism.